Business Context and Reporting Period
Company: Merit Medical Systems, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2009
Business Overview: Merit Medical Systems designs, manufactures, and markets medical devices, primarily for interventional radiology, cardiology, and gastroenterology. The company operates manufacturing facilities in the U.S. and Ireland.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2009 | Nine Months Ended Sep 30, 2009 | Three Months Ended Sep 30, 2008 | Nine Months Ended Sep 30, 2008 |
|---|---|---|---|---|
| Net Sales | $66.8 million | $190.0 million | $58.2 million | $169.1 million |
| Gross Profit | $28.5 million | $81.5 million | $23.7 million | $69.8 million |
| Gross Margin | 42.7% | 42.9% | 40.7% | 41.3% |
| Net Income | $6.1 million | $17.5 million | $5.2 million | $15.3 million |
| Diluted EPS | $0.21 | $0.61 | $0.18 | $0.54 |
| Cash from Operations (9mo) | $23.5 million | $19.0 million | ||
| Cash and Equivalents (Sep 30, 2009) | $5.8 million | $34.0 million (Dec 31, 2008) | ||
| Working Capital | $55.9 million | $84.3 million (Dec 31, 2008) |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 15% for the quarter and 12% for the nine-month period compared to 2008. Growth was driven by increased sales of custom kits, stand-alone devices, and catheters, as well as contributions from recent acquisitions (Alveolus, Hatch, Biosearch).
- Margin Expansion: Gross margins improved to 42.7% (Q3) and 42.9% (9mo) from 40.7% and 41.3% in the prior year. Improvements were attributed to lower fixed overhead unit costs, reduced material costs, and a favorable Euro-to-U.S. dollar exchange rate.
- Expense Increases: Selling, general, and administrative (SG&A) expenses rose 17% (Q3) and 19% (9mo), while R&D expenses increased 51% (Q3) and 22% (9mo). These increases were primarily due to integration costs and operational expansion related to the Alveolus and Hatch acquisitions.
- Liquidity: Cash and cash equivalents decreased significantly from $34.0 million to $5.8 million. This reduction was primarily due to $34.7 million in cash paid for acquisitions and $2.5 million in stock repurchases, partially offset by strong operating cash flow.
- Acquisitions: The company completed three major asset purchases in 2009: Alveolus (non-vascular stents), Hatch (EN Snare retrieval system), and Biosearch (biliary stents). These transactions added significant goodwill and intangible assets to the balance sheet.
Guidance, Outlook, and Risks
- Outlook: Management believes current sources of liquidity are adequate to fund operations and future growth. The company continues to invest in property and equipment to increase production capacity and automate processes.
- Subsequent Event: On October 21, 2009, Merit entered into an exclusive license and supply agreement with Vysera Biomedical Limited for valve technology and purchased shares in Vysera for approximately €1.6 million.
- Risk Factors:
- Healthcare Reform: Potential U.S. healthcare reform initiatives, including taxes on medical device sales or reduced reimbursements, could materially adversely affect financial results.
- Acquisition Integration: Risks associated with integrating recent acquisitions and achieving projected synergies.
- Foreign Currency: Exposure to fluctuations in the Euro and British Pound, though partially hedged.
- Regulatory: Delays in obtaining or maintaining regulatory approvals for new products.
Investor Verification Checklist
- Acquisition Integration: Verify the progress of integrating Alveolus, Hatch, and Biosearch assets and whether projected synergies are being realized.
- Cash Position: Monitor the significant drawdown in cash reserves ($28.3 million decrease) and the company's reliance on operating cash flow versus external financing.
- Healthcare Policy Impact: Assess the potential financial impact of pending U.S. healthcare reform legislation, specifically regarding device taxes and reimbursement rates.
- Inventory Levels: Review the $9.7 million increase in inventory to ensure it aligns with sales growth and does not indicate obsolescence risks.
- Goodwill and Intangibles: Evaluate the $19.8 million increase in goodwill and the amortization schedule of new intangible assets, which will impact future earnings.